Drug Profile
Research programme: gastric acid pump antagonists - RaQualia Pharma
Alternative Names: RQ-00000774Latest Information Update: 30 Jun 2020
Price :
$50
*
At a glance
- Originator Pfizer
- Developer RaQualia Pharma
- Class
- Mechanism of Action H(+) K(+)-exchanging ATPase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastro-oesophageal reflux